Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PRKCZ | Q05513 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 2/20 | 0.51 |
| ▸ | FHIT | P49789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10714711 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL162443 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL8197710 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL1796103 | 0.79 | GRM6 (0.46) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL25802180 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL9097409 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL8907488 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL10532585 | 0.79 | ALDH1A1 (0.75) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL4102678 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ | |
| SCHEMBL16643764 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MAPK1SMN1; SMN2POLBPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356164-A1 | 2-AMINOSELENOPHEN COMPOUNDS WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | ZHUHAI JINAN SELENIUM SOURCE NANOTECHNOLOGY CO., LTD. (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2066675-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | Wyeth (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008039414-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | WYETH (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | WYETH | 2008-03-27 | — | — | US | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| US-6734180-B1 | NF-κB inhibitor comprising an indan derivative as an active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0609371-B1 | THIENOPYRAZINE-2,3-DIONES USEFUL FOR TREATING CNS DISORDERS, AND THEIR PREPARATION. | NOVO NORDISK AS (DK) | 1996-04-24 | — | — | EP | disclosed |
| EP-0609371-A1 | THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1994-08-10 | — | — | EP | disclosed |
| US-5284847-A | Neurological and psychological disorders; antagonist at the glycine binding site on the N-methyl-D-aspartate receptor complex | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| WO-1993008197-A1 | THIENOPYRAZINE-2,3-DIONES AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |
| US-4692461-A | PLANT PROTECTION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| EP-0224140-A1 | Thienyl urea derivatives | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | MAP4K2, MAP4K1, MAP4K3 | ALDH1A1 3947/4885MAPK1 102/4885SMN1; SMN2 4367/4885 |
| US-20220356164-A1 | 2-AMINOSELENOPHEN COMPOUNDS WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME | SLC11A2, LSS, AASDHPPT | ALDH1A1 2155/4885MAPK1 2588/4885SMN1; SMN2 4340/4885 |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | ALDH1A1 2533/4885MAPK1 31/4885SMN1; SMN2 4165/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | ALDH1A1 423/4885MAPK1 1734/4885SMN1; SMN2 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.